CNSP: CNS Pharmaceuticals, Inc. Stock

by  •  • Comments Off on CNSP: CNS Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5.74
Enterprise Value ($M) -1.20
Book Value ($M) 3.35
Book Value / Share 0.06
Price / Book 1.71
NCAV ($M) 3.33
NCAV / Share 0.06
Price / NCAV 1.72

Profitability (mra)
Return on Invested Capital (ROIC) -5.04
Return on Assets (ROA) -10.03
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.82
Current Ratio 1.82

Balance Sheet (mrq) ($M)
Current Assets 7.39
Assets 7.41
Liabilities 4.06
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Armistice Capital, Llc 3.20 57.10
08-02 13D Cortice Biosciences, Inc. 5.70
07-02 13G Forster Robert 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September, 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13
2024-08-14 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June, 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15
2024-05-15 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March, 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 1
2024-04-01 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-31 2,457,791 5,256,403 46.76
2025-01-30 2,056,744 4,276,662 48.09
2025-01-29 2,842,341 6,993,367 40.64
2025-01-28 3,783,187 7,322,864 51.66
2025-01-27 3,323,529 7,739,615 42.94

(click for more detail)

Similar Companies
CLNN – Clene Inc. CLRB – Cellectar Biosciences, Inc.
CMPX – Compass Therapeutics, Inc. CNTX – Context Therapeutics Inc.
COCP – Cocrystal Pharma, Inc.


Financial data and stock pages provided by
Fintel.io